How you could have turned $10,000 into $370,000 in five years on the ASX

Did you know that a $10,000 investment in A2 Milk Company Ltd (ASX:A2M), Appen Ltd (ASX:APX), and Clinuvel Pharmaceuticals Limited (ASX:CUV) five years ago would have created significant wealth?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share market has been a great place to invest your money over the last five years. During this time the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has delivered an average return of approximately 7.1% per annum.

This means that a $10,000 investment in the index five years ago would have grown to be worth just over $14,000 today.

Whilst this is a solid return in such a short space of time, it pales in comparison to some of the returns that have been made on the market.

The following seven shares have beaten the market by some distance over the period:

The A2 Milk Company Ltd (ASX: A2M) share price has been trading on the ASX for just under four years. If you'd picked up $10,000 worth of shares in April 2015 at 56 cents, that investment would have grown to be worth $247,000 today.

The Altium Limited (ASX: ALU) share price has provided a total return of approximately 74.1% per annum over the last five years. This would have turned a $10,000 investment into $160,000.

The Appen Ltd (ASX: APX) share price has been trading on the ASX since January 2015. If you picked up $10,000 worth of the shares of the developer of high-quality, human annotated datasets that month for 63 cents, that investment would now be worth $373,000.

The Bellamy's Australia Ltd (ASX: BAL) share price has been a big mover since hitting the ASX boards in August 2014. So much so, a $10,000 investment in the infant formula company's shares that month would now be worth a cool $66,000.

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has provided investors with an average total return of 74.9% per annum over the last five years. This means that a $10,000 investment in the pharmaceutical company's shares five years ago would be worth almost $164,000 today.

The Nanosonics Ltd (ASX: NAN) share price has been a strong performer over the last five years, providing shareholders with an average total return of 37.1% annum. This would have turned a $10,000 investment in the infection control specialist's shares five years ago into $48,500 today.

The Pro Medicus Limited (ASX: PME) share price has provided investors with a staggering average annual return of 81.9% per annum over the last five years. Which means $10,000 invested in the healthcare technology company's shares would have grown to be worth $199,000.

Foolish Takeaway.

Whilst returns of this nature are reasonably rare, they do happen, and I feel confident in five years we'll be looking back at another group of shares that have done the same.

The key will be finding these shares before they take off.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia owns shares of A2 Milk, Altium, and Appen Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

Here are the top five ASX 200 shares in Macquarie's model growth portfolio

These ASX 200 shares are highly rated by analysts at Macquarie.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Growth Shares

3 ASX shares to buy in 2024 and hold for the next 10 years

Analysts think these top shares are in the buy zone right now.

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Growth Shares

4 ASX growth shares I think will benefit from interest rate cuts in 2024

Not only will home loan holders rejoice, investors of these stocks could also be yelling with joy when the Reserve…

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Growth Shares

3 of the best ASX growth shares to buy now

Analysts see plenty of upside for these buy-rated shares.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Growth Shares

Here's why analysts love these buy-rated ASX 200 growth shares

There's a reason analysts are feeling bullish about these companies.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Growth Shares

Big returns could be coming for high-flying Lovisa shares

Morgans doesn't believe it is too late to snap up this hot stock.

Read more »

Smiling young parents with their daughter dream of success.
Growth Shares

Why these ASX 200 growth shares could be top buys now

Analysts are feeling bullish about these growth stocks. Let’s see what they’re saying.

Read more »

Concept image of a man in a suit with his chest on fire.
Growth Shares

Ignore the noise and buy this hot ASX growth stock

A recent pullback may have created a buying opportunity according to Bell Potter.

Read more »